DecipHER Trial: Dendritic Cell Vaccine for Early-Stage Triple Negative and ER Low Positive Breast Cancer
This study, called the DecipHER Trial, is looking at whether an investigational vaccine called Dendritic Cell (DC) vaccine can help people with early-stage Triple Negative Breast Cancer or ER (estrogen receptor) Low Positive Breast Cancer. You may be able to join if you have HER2-negative breast cancer and meet other criteria. The vaccine involves injections of HER2-primed and HER3-primed Dendritic cells. Researchers want to find the highest safe dose of this vaccine when given with standard chemotherapy. The current recruitment status is unclear, and the study plans to enroll 30 participants.
- Study design
- This is an interventional study with an unclear phase, planning to enroll 30 participants. It is testing the maximum tolerated dose of the investigational vaccine.
- What's involved
- Participants will receive 8 intratumoral injections of Dendritic cells, given twice per week (3 days apart). These injections will alternate between HER2-primed and HER3-primed cells.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint, Maximum Tolerated Dose, is measured at 4 weeks after the start of treatment. Further follow-up is not specified.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT05504707
DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer
Recruiting
PHASE1Ages 18+InterventionalTreatmentH. Lee Moffitt Cancer Center and Research InstituteInvestigator-initiated
~30 participants
Updated 2026-02-05 on ClinicalTrials.gov
What's tested:HER2 - primed Dendritic cellsHER3 - primed Dendritic cells
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Maximum Tolerated Dose (MTD)
Measured over 4 weeks after start of treatment
Conditions
Where it's being run
1 sites across 1 statesFlorida1
Study leadership
- Ricardo Costa, MD · PRINCIPAL_INVESTIGATOR · Moffitt Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
A diagnosis of HER2-negative breast cancer.
Diagnosis of HR negative or HR low positive tumor.
Clinical stage T1c, nodal stage N1-N2 or stage T2-4, nodal stage N0-N2 breast cancer.
Participant must be medically and surgically appropriate to undergo neoadjuvant chemotherapy regimen followed by standard of care local therapy as determined by their treating physician.
Age ≥18 years.
ECOG performance status 0 or 1.
Patients must have normal organ and marrow function, as defined below, within 14 days of registration:
\*Absolute neutrophil count (ANC) ≥ 1500/μL
\*Platelets ≥ 75 000/μL
\*Total bilirubin ≤ 1.5 x institutional ULN, except patients with Gilbert's syndrome in whom total bilirubin must be \< 3.0 mg/dL
\*AST/ALT ≤ 3 x institutional ULN
\*Creatinine ≤ 1.5 x institutional ULN
Left ventricular ejection fraction above institutional lower limit of normal (by echocardiogram or MUGA scan).
Female patients of childbearing potential must agree to use dual methods of contraception and have a negative serum pregnancy test at screening. Acceptable methods of contraception are condoms with contraceptive foam, oral, implantable or injectable contraceptives, contraceptive patch, intrauterine device, diaphragm with spermicidal gel, or a sexual partner who is surgically sterilized or post-menopausal. Effective methods of contraception must be used throughout the study and for 5 months following the last dose. To show that women do not have childbearing potential, postmenopausal women must be amenorrheic for at least 12 months naturally (and not because of/following chemotherapy) or patients must be surgically sterile.
Ability to understand and the willingness to sign a written informed consent agreement prior to study registration.
Exclusion
Patients who received prior anthracycline-based chemotherapy for the treatment of any cancer.
Patients with inflammatory breast cancer.
Patients must not be receiving any other investigational agents or active antineoplastic therapies.
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune-suppressive treatment, including chronic prolonged systemic corticosteroid use (defined as corticosteroid use lasting one month or more).
Female patients who are pregnant or nursing.
No other prior malignancy is allowed, except for the following: a. adequately treated basal-cell or squamous-cell skin cancer, b. in situ cervical cancer, c. or any other cancer from which the patient has been disease free for at least 3 years.
History of testing positive for human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS).
History of positive test for Hepatitis B or Hepatitis C virus indicating acute or chronic infection.
Patients who have received a live attenuated vaccine ≤ 30 days prior to registration.
Unable to comply with the treatment schedule and study procedures for any reason.
Previously treated with breast cancer-directed vaccine therapies in prior 3 months.
Previously treated with any form HER2- or HER3-primed DC1 therapy.
What this trial measures
- Maximum Tolerated Dose (MTD)4 weeks after start of treatment
Maximum Tolerated Dose (MTD) of HER2- and HER3- primed DC1 study vaccines. The MTD will be defined as the highest dose level at which \< 2 of 6 patients experience dose-limiting toxicities (DLTs).